Gilead Sciences, Inc. (NASDAQ:GILD) CFO Sells $781,660.00 in Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CFO Andrew D. Dickinson sold 8,500 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $91.96, for a total transaction of $781,660.00. Following the completion of the transaction, the chief financial officer now owns 132,373 shares of the company’s stock, valued at approximately $12,173,021.08. This trade represents a 6.03 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Gilead Sciences Stock Up 0.4 %

Gilead Sciences stock opened at $91.09 on Friday. The firm has a market capitalization of $113.52 billion, a price-to-earnings ratio of 1,012.11, a price-to-earnings-growth ratio of 2.38 and a beta of 0.18. The firm’s fifty day moving average price is $90.48 and its two-hundred day moving average price is $80.22. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $98.90. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.44. The business had revenue of $7.55 billion for the quarter, compared to analysts’ expectations of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm’s revenue for the quarter was up 7.0% compared to the same quarter last year. During the same quarter last year, the firm earned $2.29 EPS. On average, equities research analysts predict that Gilead Sciences, Inc. will post 4.35 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 30th. Investors of record on Friday, December 13th will be given a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 3.38%. The ex-dividend date of this dividend is Friday, December 13th. Gilead Sciences’s payout ratio is currently 3,422.22%.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on GILD. Leerink Partners raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and raised their price target for the company from $74.00 to $96.00 in a research note on Monday, October 21st. JPMorgan Chase & Co. raised their target price on Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. The Goldman Sachs Group increased their price target on Gilead Sciences from $74.00 to $84.00 and gave the company a “neutral” rating in a research note on Thursday, November 7th. BMO Capital Markets lifted their price objective on Gilead Sciences from $94.00 to $102.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. Finally, Sanford C. Bernstein began coverage on Gilead Sciences in a report on Thursday, October 17th. They issued an “outperform” rating and a $105.00 target price on the stock. Twelve research analysts have rated the stock with a hold rating, twelve have issued a buy rating and four have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and an average price target of $96.43.

Hedge Funds Weigh In On Gilead Sciences

Hedge funds have recently bought and sold shares of the company. nVerses Capital LLC bought a new position in shares of Gilead Sciences during the third quarter valued at about $25,000. Valued Wealth Advisors LLC increased its stake in Gilead Sciences by 101.9% in the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 161 shares during the last quarter. Cedar Wealth Management LLC lifted its position in shares of Gilead Sciences by 51.6% during the 2nd quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 160 shares in the last quarter. Strategic Investment Solutions Inc. IL purchased a new position in shares of Gilead Sciences in the 2nd quarter worth approximately $33,000. Finally, Financial Connections Group Inc. bought a new position in shares of Gilead Sciences in the second quarter valued at approximately $34,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.